EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01942005 |
Recruitment Status
:
Completed
First Posted
: September 13, 2013
Last Update Posted
: December 4, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Immunosuppression Neoplasm |
Study Type : | Observational |
Actual Enrollment : | 144 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | May 2014 |
Actual Study Completion Date : | May 2014 |
- Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [ Time Frame: 7 years ]
- correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients in an immunosuppressive condition either by immunosuppressants or by HIV infection
Exclusion Criteria:
- written informed consent not given

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01942005
Switzerland | |
University Hospital Basel, Dermatology | |
Basel, Basel Stadt, Switzerland, 4031 |
Principal Investigator: | Andreas Arnold, MD | University Hospital Basel, Dermatology, CH-4031 Basel |
Responsible Party: | Andreas Arnold, Dr. med. Andreas Arnold, senior physician, University Hospital, Basel, Switzerland |
ClinicalTrials.gov Identifier: | NCT01942005 History of Changes |
Other Study ID Numbers: |
11/10 |
First Posted: | September 13, 2013 Key Record Dates |
Last Update Posted: | December 4, 2014 |
Last Verified: | December 2014 |